Tyme Reports Year-End Financial Results For 2015
NEW YORK--(BUSINESS WIRE)--Tyme Technologies, Inc. (OTC QB: TYMI), a clinical-stage pharmaceutical company focused on discovering and developing highly-targeted cancer therapeutics for a broad range of oncology indications has reported financial results for the year ended December 31, 2015.
"Our development program for our lead compound, SM-88, continues to evolve as we work towards the initiation of our first Phase II clinical trial. We are preparing protocols for a Phase II breast cancer study, as well as other Phase II trials to be initiated in 2016, most likely to include prostate, pancreatic and non-small cell lung cancers.
"Our development program for our lead compound, SM-88, continues to evolve as we work towards the initiation of our first Phase II clinical trial. We are preparing protocols for a Phase II breast cancer study, as well as other Phase II trials to be initiated in 2016, most likely to include prostate, pancreatic and non-small cell lung cancers.